Welcome to our dedicated page for Amphastar Pharma SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Amphastar is a biopharmaceutical company focused on complex generic and proprietary injectable, inhalation, and intranasal products and insulin API products, and its filings offer detailed insight into how this business is structured and governed.
Investors reviewing AMPH filings will find current reports on Form 8-K that describe material events such as license agreements, contract research agreements, manufacturing and distribution amendments, and related-party transactions with entities affiliated with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. These 8-Ks outline key terms for agreements covering proprietary peptides, AMP-110, recombinant peptide research cell banks for AMP-107, and regional distribution of BAQSIMI®.
Amphastar also files earnings-related 8-Ks that furnish press releases summarizing quarterly financial results, including net revenues, net income, and non-GAAP measures such as adjusted net income and adjusted diluted EPS. These disclosures explain how the company evaluates its operating performance and reconcile non-GAAP metrics to GAAP figures.
Through Stock Titan, users can monitor real-time updates from EDGAR as new Amphastar filings appear, including annual reports on Form 10-K and quarterly reports on Form 10-Q when available. AI-powered summaries help explain the significance of complex agreements, highlight changes in licensing and manufacturing arrangements, and surface important details about pipeline assets, manufacturing footprint, distribution partnerships, and governance matters. The filings page also makes it easier to track board and management changes, share repurchase authorizations, and other corporate actions that Amphastar reports to the SEC.
Insider sale notice for AMPH: This Form 144 shows a proposed sale of 500 shares of Amphastar Pharmaceuticals common stock through UBS Financial Services on or about 10/01/2025, with an aggregate market value listed as $13,370.00. The shares were originally acquired as RSUs on 06/07/2022. The filer previously sold three blocks of 500 shares each during July, August and September 2025, generating gross proceeds of $11,733.95, $10,415.75, and $15,491.65 respectively. The filing lists total shares outstanding as 46,495,077, indicating the planned sale is a small fraction of the company’s outstanding shares. The notice includes the signer’s representation that no undisclosed material adverse information about the issuer is known.
Amphastar Pharmaceuticals entered into a three-year contract research agreement with Nanjing Hanxin Pharmaceutical TechnologyAMP-107 and license them under a fully paid, exclusive, perpetual, transferable, sub-licensable worldwide license.
All title to the RCBs and related development and manufacturing know-how, including engineering, scientific data, designs, and procedures, will belong to Amphastar. The total cost of the agreement will not exceed approximately $2.8 million, paid in Chinese yuan, including an initial payment of about $0.3 million on the effective date, with any extra work billed on a cost-plus basis subject to prior approval.
The filing notes this is a related-party transaction because Amphastar CEO Dr. Jack Zhang, COO and Chairman Dr. Mary Luo, and certain family members beneficially own a majority of Hanxin’s equity. The independent and disinterested members of the Audit Committee evaluated and approved Amphastar’s entry into the agreement.
Floyd F. Petersen, a director of Amphastar Pharmaceuticals (AMPH), sold 500 shares on 09/02/2025 under a pre-existing Rule 10b5-1 trading plan. The sales were executed at a weighted-average price of $30.9833 per share, with individual sale prices ranging from $30.60 to $31.225. Following the reported disposition, Petersen is recorded as beneficially owning 76,531 shares. The Form 4 was signed by Eva Wen by power of attorney on 09/03/2025.
Form 144 notice by Floyd Peterson for Amphastar Pharmaceuticals, Inc. (AMPH). The filer notifies a proposed sale of 500 shares of common stock through UBS Financial Services on NASDAQ with an approximate sale date of 09/02/2025 and an aggregate market value listed at $15,450.00. The shares were acquired as RSUs on 06/07/2022. The filing also discloses three sales by the same person in the past three months totaling 1,500 shares on 06/02/2025, 07/02/2025 and 08/01/2025 with combined gross proceeds of $34,984.75. The form includes the required representation that the seller is not aware of undisclosed material adverse information.
Amphastar Pharmaceuticals entered a license agreement with Nanjing Anji Biotechnology granting Amphastar exclusive rights in the United States and Canada to develop, make, use and commercialize products incorporating certain compounds, including three identified Licensed Products. Amphastar paid an $0.75 million earnest payment and a $5.25 million upfront fee on signing and agreed to up to $42 million in development milestones and up to $225 million in sales milestones, plus royalty payments capped at $22.5 million per product per year and a $60 million accumulated cap per product. Amphastar will share a percentage of sublicense income with Anji, and Anji will pay Amphastar royalties on net sales tied to Amphastar-licensed patents outside the Territory.
The agreement term runs product-by-product and region-by-region to the tenth anniversary of first commercial sale with an Amphastar option to extend up to ten additional years or until patent claims lapse. The company disclosed customary forward-looking statements and identified risks including regulatory approval, commercialization success, legal and regulatory changes, and supply-chain disruptions, and incorporated the full Agreement by reference to be filed as an exhibit.
Amphastar Pharmaceuticals (AMPH) – SEC Form 4
Director Floyd F. Petersen disclosed the sale of 500 common shares on 01 Aug 2025 at a weighted-average price of $20.8315. The transaction was executed under a Rule 10b5-1 trading plan adopted 26 Nov 2024, indicating it was pre-scheduled rather than discretionary. After the sale, Petersen directly owns 77,031 shares, so the disposition equals roughly 0.6 % of his stake and is immaterial relative to Amphastar’s total share count. No derivative securities activity or additional insider trades were reported.
The filing therefore conveys routine insider diversification without signaling a change in corporate fundamentals or outlook.